Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP225404.RATqD8_eK1_BwLZkIwpt0RhpHV6JyURzCH1x0wJYVWx1c130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP225404.RATqD8_eK1_BwLZkIwpt0RhpHV6JyURzCH1x0wJYVWx1c130_assertion type Assertion NP225404.RATqD8_eK1_BwLZkIwpt0RhpHV6JyURzCH1x0wJYVWx1c130_head.
- NP225404.RATqD8_eK1_BwLZkIwpt0RhpHV6JyURzCH1x0wJYVWx1c130_assertion description "[A phase II study of the PARP inhibitor olaparib (AstraZeneca) for cancer patients with inherited BRCA1 and BRCA2 gene mutations confirmed earlier results showing clinical benefit for advanced breast and ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP225404.RATqD8_eK1_BwLZkIwpt0RhpHV6JyURzCH1x0wJYVWx1c130_provenance.
- NP225404.RATqD8_eK1_BwLZkIwpt0RhpHV6JyURzCH1x0wJYVWx1c130_assertion evidence source_evidence_literature NP225404.RATqD8_eK1_BwLZkIwpt0RhpHV6JyURzCH1x0wJYVWx1c130_provenance.
- NP225404.RATqD8_eK1_BwLZkIwpt0RhpHV6JyURzCH1x0wJYVWx1c130_assertion SIO_000772 23847380 NP225404.RATqD8_eK1_BwLZkIwpt0RhpHV6JyURzCH1x0wJYVWx1c130_provenance.
- NP225404.RATqD8_eK1_BwLZkIwpt0RhpHV6JyURzCH1x0wJYVWx1c130_assertion wasDerivedFrom befree-20150227 NP225404.RATqD8_eK1_BwLZkIwpt0RhpHV6JyURzCH1x0wJYVWx1c130_provenance.
- NP225404.RATqD8_eK1_BwLZkIwpt0RhpHV6JyURzCH1x0wJYVWx1c130_assertion wasGeneratedBy ECO_0000203 NP225404.RATqD8_eK1_BwLZkIwpt0RhpHV6JyURzCH1x0wJYVWx1c130_provenance.